DE3843241C2 - - Google Patents
Info
- Publication number
- DE3843241C2 DE3843241C2 DE3843241A DE3843241A DE3843241C2 DE 3843241 C2 DE3843241 C2 DE 3843241C2 DE 3843241 A DE3843241 A DE 3843241A DE 3843241 A DE3843241 A DE 3843241A DE 3843241 C2 DE3843241 C2 DE 3843241C2
- Authority
- DE
- Germany
- Prior art keywords
- amino acids
- mixture
- renal
- kidney
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 210000003734 kidney Anatomy 0.000 claims abstract description 15
- 231100000331 toxic Toxicity 0.000 claims abstract description 9
- 230000002588 toxic effect Effects 0.000 claims abstract description 9
- 229940024606 amino acid Drugs 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 229960004316 cisplatin Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 abstract description 14
- 239000000824 cytostatic agent Substances 0.000 abstract description 10
- 230000001085 cytostatic effect Effects 0.000 abstract description 9
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 5
- 229940124589 immunosuppressive drug Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 9
- 230000003589 nefrotoxic effect Effects 0.000 description 8
- 230000004900 autophagic degradation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 231100000381 nephrotoxic Toxicity 0.000 description 6
- 210000003292 kidney cell Anatomy 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 230000001607 nephroprotective effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 210000005234 proximal tubule cell Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000012998 acute renal failure Diseases 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000013878 renal filtration Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001611093 Stimula Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 239000002800 charge carrier Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 tral amino acids Chemical class 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3843241A DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
| SU894830956A RU2077883C1 (ru) | 1988-12-22 | 1989-12-21 | Композиция для внутривенного введения для защиты почек от токсического действия нефротоксичных цитостатических средств и иммуносупрессоров |
| PCT/DE1989/000780 WO1990006769A1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung |
| JP2500961A JPH078790B2 (ja) | 1988-12-22 | 1989-12-21 | 腎保護持続注入液 |
| DE58908288T DE58908288D1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
| EP90900071A EP0408691B1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung |
| AU48079/90A AU4807990A (en) | 1988-12-22 | 1989-12-21 | Antinephrotoxic perfusion solution |
| ES90900071T ES2063332T3 (es) | 1988-12-22 | 1989-12-21 | Solucion de infusion nefroprotectora. |
| AT90900071T ATE110570T1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
| US07/873,579 US5290538A (en) | 1988-12-22 | 1992-04-21 | Nephro protective infusion solutions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3843241A DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3843241A1 DE3843241A1 (de) | 1990-06-28 |
| DE3843241C2 true DE3843241C2 (enExample) | 1990-11-22 |
Family
ID=6369857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3843241A Granted DE3843241A1 (de) | 1988-12-22 | 1988-12-22 | Nephroprotektive infusionsloesung |
| DE58908288T Expired - Fee Related DE58908288D1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE58908288T Expired - Fee Related DE58908288D1 (de) | 1988-12-22 | 1989-12-21 | Nephroprotektive infusionslösung. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0408691B1 (enExample) |
| JP (1) | JPH078790B2 (enExample) |
| AT (1) | ATE110570T1 (enExample) |
| AU (1) | AU4807990A (enExample) |
| DE (2) | DE3843241A1 (enExample) |
| ES (1) | ES2063332T3 (enExample) |
| RU (1) | RU2077883C1 (enExample) |
| WO (1) | WO1990006769A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060672B2 (en) | 2001-10-19 | 2006-06-13 | Isotechnika, Inc. | Cyclosporin analog formulations |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6224776B1 (en) | 1996-05-24 | 2001-05-01 | Cultor Corporation | Method for fractionating a solution |
| US6096785A (en) * | 1996-07-30 | 2000-08-01 | Novartis Nutrition Ag | Amino acid compositions and use thereof in treating renal dysfunction |
| UA65587C2 (en) * | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
| NZ513926A (en) * | 1999-02-23 | 2001-09-28 | Univ California | Methods of treatment of mitochondrial disorders |
| FI20010977A7 (fi) | 2001-05-09 | 2002-11-10 | Danisco Sweeteners Oy | Kromatografinen erotusmenetelmä |
| JPWO2005094813A1 (ja) * | 2004-03-31 | 2008-02-14 | 味の素株式会社 | 腎疾患用薬剤 |
| US9669010B2 (en) | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
| EP2928461B1 (en) * | 2012-12-06 | 2019-08-21 | Bio Health Solutions, LLC | Treatment for chronic kidney disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3414491A1 (de) * | 1984-04-17 | 1985-10-24 | Hans Dr. 8202 Bad Aibling Dietl | L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen |
-
1988
- 1988-12-22 DE DE3843241A patent/DE3843241A1/de active Granted
-
1989
- 1989-12-21 RU SU894830956A patent/RU2077883C1/ru active
- 1989-12-21 EP EP90900071A patent/EP0408691B1/de not_active Expired - Lifetime
- 1989-12-21 ES ES90900071T patent/ES2063332T3/es not_active Expired - Lifetime
- 1989-12-21 WO PCT/DE1989/000780 patent/WO1990006769A1/de not_active Ceased
- 1989-12-21 JP JP2500961A patent/JPH078790B2/ja not_active Expired - Lifetime
- 1989-12-21 DE DE58908288T patent/DE58908288D1/de not_active Expired - Fee Related
- 1989-12-21 AU AU48079/90A patent/AU4807990A/en not_active Abandoned
- 1989-12-21 AT AT90900071T patent/ATE110570T1/de not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060672B2 (en) | 2001-10-19 | 2006-06-13 | Isotechnika, Inc. | Cyclosporin analog formulations |
| US7429562B2 (en) | 2001-10-19 | 2008-09-30 | Isotechnika Inc. | Cyclosporin analog formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03502805A (ja) | 1991-06-27 |
| ES2063332T3 (es) | 1995-01-01 |
| AU4807990A (en) | 1990-07-10 |
| EP0408691B1 (de) | 1994-08-31 |
| ATE110570T1 (de) | 1994-09-15 |
| RU2077883C1 (ru) | 1997-04-27 |
| EP0408691A1 (de) | 1991-01-23 |
| WO1990006769A1 (de) | 1990-06-28 |
| JPH078790B2 (ja) | 1995-02-01 |
| DE58908288D1 (de) | 1994-10-06 |
| DE3843241A1 (de) | 1990-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69535104T2 (de) | Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose | |
| Williams et al. | Exogenous nerve growth factor increases the activity of high‐affinity choline uptake and choline acetyltransferase in brain of Fisher 344 male rats | |
| DE2260189C2 (de) | Injizierbare Aminosäurepräparate | |
| Beart et al. | γ-Aminobutyric acid in the rat peripheral nervous system, pineal and posterior pituitary | |
| DE69127087T2 (de) | Wachstumsfaktor und glutamin enthaltendes produkt und verwendung des wachstumsfaktors zur behandlung der darmschleimhaut | |
| DE3843241C2 (enExample) | ||
| DE2431776A1 (de) | Neue peptidzusammensetzungen | |
| DE3650620T2 (de) | Behandlungsverfahren kataboler dysfunktion | |
| DE2834001A1 (de) | Neue pepstatinderivate und verfahren zu ihrer herstellung | |
| EP0370994B1 (de) | Behandlung von durch Glucose ausgelöster Quervernetzung von Collagen bei Diabetes mellitus-Patienten durch Arginin, Spermidin, Kreatin oder Agmatin | |
| US5290538A (en) | Nephro protective infusion solutions | |
| DE2946563C2 (de) | Aminosäurelösung zur parenteralen Infusion | |
| DE69130292T2 (de) | Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on | |
| Lundgren et al. | Plasma renin activity before and after allogeneic kidney transplantation in man | |
| DE2750159C3 (de) | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung | |
| US4261980A (en) | Method for prophylaxis and/or treatment of sickle cell disease | |
| DE2944341C2 (enExample) | ||
| DE69533742T2 (de) | Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis | |
| DE2531204C2 (de) | L-Aminosäuregemische für die parenterale oder orale Ernährung | |
| Rivet et al. | Phenytoin preferentially inhibits L-type calcium currents in whole-cell patch-clamped cardiac and skeletal muscle cells | |
| CA2378726A1 (en) | Compositions containing muscle-derived active agents | |
| CH637915A5 (de) | Angiotensin-2-antagonistisch wirkende peptide und verfahren zur herstellung dieser verbindungen. | |
| Slifkin et al. | The nature of amino-acid chloranil complexes | |
| DE3414491A1 (de) | L-aminosaeurengemische fuer die parenterale und orale anwendung bei nierenerkrankungen | |
| CH634854A5 (de) | Verfahren zur herstellung organopeptidhaltiger substanzen mit insulinaehnlicher wirksamkeit aus blut oder blutbestandteilen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |